5414x (2026)

: Introduced next-generation automated flow cell lines and strengthened quality assurance to ISO 13485 standards.

: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas.

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year. : Introduced next-generation automated flow cell lines and

: £12.9 million (+27.4%), supported by synthetic biology.

: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update Gross Profit : £61

: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth :

The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights: Leadership Update : 58

Co-founder and CEO announced he will step down from his role and the board by the end of 2026.